Author Archives: admin


Stem Cell Clinic > Articles by: admin

Clinical Laboratory Services Market 2020 Strategies and Insight Driven Transformation to 2027 | Global Players Mayo Foundation for Medical Education…

By Gene Therapy Clinics

Data Bridge Market Research (DBMR) has published a latest market research report on Global Clinical Laboratory Services Market . The global report is prepared in collaboration with the leading industry experts & dedicated research analyst team to provide an enterprise with in-depth market insights and help them to take crucial business decisions. This report covers current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-clinical-laboratory-services-market&rp

Clinical Laboratory Services Market business research report aids to stay up-to-date about the entire market and also offer holistic view of the market. Market definition, market segmentation, key developments in the market, competitive analysis & research methodology are the major topics covered in this report which are thoroughly studied with the best tools and techniques. Analysts have used a SWOT analysis and a Porters five forces analysis to estimate the global Clinical Laboratory Services market thoroughly. Both these tools ensure accurate assessment of the market & including the intensity of the competitive rivalry present in the market. This market analysis enables readers to deal with a wide range of business issues and come to logical conclusions that can be used for making well-informed decisions.

Market Analysis and Insights:Global Clinical Laboratory Services Market

Clinical laboratory services market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.2% in the forecast period of 2020 to 2027 and expected to reach USD 217,941.33 million by 2027 from USD 134,692.52 million in 2019. Rising demand for early and accurate disease diagnosis is the factors for the market growth.

The major players covered in the Clinical Laboratory Services Market are Mayo Foundation for Medical Education and Research (MFMER), Laboratory Corporation of America Holding, Quest Diagnostics Incorporated, Spectra Laboratories (A Subsidiary of Fresenius Medical Care AG & Co. KGaA), DaVita Inc., Eurofins Scientific, UNILABS, SYNLAB International GmbH, MIRACA HOLDINGS Inc., Sonic Healthcare, ACM Global Laboratories, amedes Group, LifeLabs, Alere (A Subsidiary of Abbott), Charles River, Siemens Healthineers AG, BioReference Laboratories, Inc., NeoGenomics Laboratories, Inc., KingMed Diagnostics, Genomic Health, among other players domestic and global. Clinical laboratory services market share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-clinical-laboratory-services-market&rp

Clinical laboratory services is playing significant role to enable doctors to make appropriate clinical and diagnostic decisions across various levels of health care services. Increasing demand for diagnostic tests is augmenting the market growth as they are used for clinical diagnoses tests.

Clinical laboratory services demand has been increased with rising infectious diseases worldwide as compared to the past few years which will accelerate the market growth. Clinical diagnostic advancement methods for diagnoses of diseases in the clinical laboratory. For instance, Technological advancement in the clinical diagnostic methods have made diagnostic tests easier to use and more accurate as well as also led to more precise as well as more timely reports. Development in database management tools and wide acceptance of point-of-care (POC) testing solutions will also drive the market. Lack of skilled and certified professionals will hamper the Clinical laboratory services market as which further creates new opportunities for clinical laboratory services with growing adoption of digital pathology platforms. Such policies support Clinical Laboratory Services market growth in the forecast period to 2027.

This clinical laboratory services market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Clinical Laboratory Services Market Scope and Market Size

Global clinical laboratory services market is segmented of the basis of specialty, provider and application. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on specialty, the market is segmented into clinical chemistry testing, microbiology testing, hematology testing, immunology testing, cytology testing, genetic testing and drugs of abuse testing. The clinical chemistry testing segment is dominating the market due to the growing cases of chronic diseases such as liver diseases, cardiovascular diseases and blood disorders which are increasing the demand to use clinical chemistry services. Additionally, the increasing demand of point of care testing solutions which is used for the fast diagnosis of the disease is expected to help the market to growth significantly.

Rising demand of clinical laboratory services across the world is one of the prominent factors for increasing demand of clinical chemistry testing. For instance, yearly in the U.K., the usually citizen has 14 tests completed by a laboratory specialist. However in the U.S., laboratory testing is the only highest-volume medical activity and approximately 13,000 million tests are performed per year. Hence, this factor has led the patients to shift towards clinical chemistry testing because it offers a wide range of tests which are performed in the clinical laboratory testing. In the current scenario the technological advancements boost the patients reach to laboratory testing, which is becoming gradually more precise and affordable. For instance, point-of-care testing (POCT) is regularly applied in hospitals and other healthcare practices, so the patients not need to travel to the clinical laboratories for testing. The increasing use of point-of-care testing has reduced demand tests which are conventionally executed at industry laboratories.

Rising demand of early and accurate disease diagnosis across the globe is one of the prominent factors for an upsurge demand of clinical laboratory services. For instance, in 2018, World Health Organization projected that projected that an estimated 1.8 million new cases and almost 861,000 deaths occur due to colorectal cancer (CRC). This factor has increased the number of clinical laboratories around the globe as Delays in accessing cancer care are very common in the late-stage presentation, especially in lower vulnerable populations and resource settings.

Based on provider, the market is segmented into independent & reference laboratories, hospital-based laboratories, nursing and physician office-based laboratories. The hospital-based laboratories segment is dominating the market due to increasing cases of injuries in the hospitals which leads to the high patient volumes and high test demand. Additionally, the rising inclination of retail clinics for disease monitoring is expected to positively impact in the demand of hospital-based laboratories. Competences of hospitals for acquiring novel technologies and hiring of trained professionals in the disease testing units has created an opportunity for the highest revenue generation. Additionally, the clinical labs are more crucial part of any hospital.

Based on application, the market is segmented into drug discovery related services, drug development related services, bioanalytical & lab chemistry services, toxicology testing services, cell & gene therapy related services, and preclinical & clinical trial related services and other clinical laboratory services. Bioanalytical & lab chemistry services segment is dominating the market because bioanalysis is an important factor in drug discovery and development. It is established that bioanalysis is a vital part of the pharmacokinetic/pharmacodynamic categorization of a novel chemical entity from its discovery and in different phases of drug development including all preclinical and clinical stages. Additionally, lab chemistry services provide support in the chemical analysis including elemental analysis, failure analysis and project analysis.

Clinical Laboratory Services Market Country Level Analysis

The global clinical laboratory services market is analysed and market size information is provided by country by specialty, provider and application as referenced above.

The countries covered in the clinical laboratory services market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, South Africa, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil and Rest of South America as part of South America.

Country Level Analysis, By Provider

North America dominates the clinical laboratory services market as the U.S. is leader in clinical laboratory services. In North America due to better advancement in products and services, this region is dominating the clinical laboratory services. North America accounts higher healthcare expenditure, especially in U.S. Asia-Pacific is growing with the highest CAGR due to increase in medical tourism as well as increase in population. Numbers of companies in emerging countries are increasing due to increase in demand for disease diagnosis in clinics, hospitals and other areas. Additionally, the increasing number of healthcare expenditure and increasing number of hospitals and clinical diagnostic laboratories in China and India upsurge demand of clinical laboratory services. The Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of increasing infectious diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by laboratory for Clinical Laboratory Services and New Technology Penetration

Global clinical laboratory services market also provides you with detailed market analysis for every country growth in life science industry with clinical laboratory services demand impact of technological development in laboratory services and changes in regulatory scenarios with their support for the clinical laboratory services market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Clinical Laboratory Services Market Share Analysis

Global clinical laboratory services market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global clinical laboratory services market.

Many business expansion and developments are also initiated by the companies worldwide which are also accelerating the growth of global clinical laboratory services market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for Clinical Laboratory Services through expanded model range.

Customization Available:Global Clinical Laboratory Services Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-clinical-laboratory-services-market&rp

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Here is the original post:
Clinical Laboratory Services Market 2020 Strategies and Insight Driven Transformation to 2027 | Global Players Mayo Foundation for Medical Education...

COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model – PRNewswire

By Stem Cell Treatment

HOUSTON, July 21, 2020 /PRNewswire/ --FibroGenesis announced today new data supporting use of its PneumoBlast product in the battle against COVID-19.Using the widely accepted bleomycin model of lung scarring (fibrosis), Company scientists have demonstrated the administration and use of PneumoBlast induced a 51% reduction of lung fibrosis,which was statistically significant (p < .005). Importantly, when PneumoBlast was compared head to head with bone marrow derived mesenchymal stem cells (BMSCs) for COVID-19, PneumoBlast was 221% more effective. In producing the potent anti-inflammatory protein interleukin 1 receptor antagonist, which is believed to be the mechanism of scar tissue prevention by BMSC therapies currently in development, PneumoBlast was 192% more effective than BMSCs which was again, statistically significant(p < .005).

During an interview with Healthline.com, Dr. Lori Shah, transplant pulmonologist at New York-Presbyterian/Columbia University Irving Medical Center, stated "Holes in the lungs likely refers to an entity that has been dubbed 'post-COVID fibrosis,' otherwise known as post-ARDS [acute respiratory distress syndrome] fibrosis, which is irreversible and can result in severe functional limitations from patients, such as cough, shortness of breath, and need for oxygen." It has been reported that pulmonary fibrosis due to COVID-19 is occurring in increasing numbers of patients in their 20s and 30s.

"COVID-19 represents a new clinical entity which not only causes death through lung inflammation, but in some patients causes permanent lung injury through stimulation of scarring," said Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis. "The prospects that our cell therapy approach not only possesses therapeutic effects on animal models of the acute stage of COVID-19, but also benefits the long-term pathology, has our research team extremely excited."

"As the scientific and medical community is discovering more about the biological and medical consequences of the COVID-19 infection, FibroGenesis is eager to contribute to the therapeutic cure options currently being created to fight this global war against an invisible enemy," commented Pete O'Heeron, President/CEO of FibroGenesis. "While we are excited about potential vaccines in the pipeline, the fact remains that there are 3.8 million confirmed cases of COVID-19 in the U.S. and we do not know what the long-term outcomes for these patients will be. To our knowledge, we are the only cell therapy company which is creating a therapy to resolve the initial pathology of infection and also proactively tackling its long-term consequences."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 235+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit http://www.Fibro-Genesis.com.

SOURCE FibroGenesis

http://www.Fibro-Genesis.com

Originally posted here:
COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model - PRNewswire

Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit – Yahoo Finance Australia

By Stem Cell Treatment

LEXINGTON,Mass., July 21, 2020 /PRNewswire/ --Agenus Inc.(NASDAQ: AGEN), an immuno-oncology(I-O) companywith apipelineofimmunecheckpointantibodies, adoptive cell therapies and cancer vaccines,announcedtoday that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian Hospital, will discuss AgenTus Therapeutics, Inc.'s (a subsidiary of Agenus) allogeneic iNKT cell therapy approach for infectious diseases at the B. Riley Virtual Infectious Disease Summit Therapeutics Day on a Panel entitled Pursuing Curative Cell Therapy Approaches.

Date: Tuesday, July 21, 2020

Time: 3:00 PM 4:00 PM ET

Title: Pursuing Curative Cell Therapy Approaches Cell Therapy has become a fast-changing field after becoming a powerful clinical therapy for late line cancer patients with the approval of the first generation CD19+ CAR T cell treatments (Yescarta and Kymriah). Participants in the panel include AgenTus Therapeutics, a biotech company and subsidiary of Agenus Inc. developing new cancer treatments, including AGENT-797, an early unmodified allogeneic iNKTcell therapy, Magenta Therapeutics, a cell therapy company developing novel cell therapies including MGTA-456, a stem -cell production therapy, and SQZ Biotechnologies Company, a biotech company developing oncology drugs including APC HPV, an autologous based therapy for several types of cancer.

Agenus Inc.Jennifer Buell, Ph.D. President and Chief Operating Officer Manuel Hidalgo, M.D. Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian

Excision BioTherapeuticsDaniel Dornbusch - Chief Executive Officer

Pluristem Therapeutics (PSTI)Racheli Ofir Vice President of Research & IP

About AgenTus Therapeutics, Inc.AgenTus Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of breakthrough allogeneic iNKT cells in the unmodified and modified with engineered receptors, such as T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge the human immune system cells to seek and destroy cancer. AgenTus also aims to advance adoptive cell therapy formats which would enable off-the-shelf living drugs. AgenTus has locations inLexington, MAandCambridge, UK. For more information, please visitwww.agentustherapeutics.com.

About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit http://www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Contact:Agenus Inc.Jennifer Buell, PhD 781-674-4420 Jennifer.Buell@agenusbio.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/agenus-to-participate-in-a-panel-on-cell-therapy-for-infectious-diseases-at-the-b-riley-virtual-infectious-disease-summit-301097296.html

SOURCE Agenus Inc.

Read the original:
Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit - Yahoo Finance Australia

Charles Darwin Investigated Goosebumps Now Harvard Scientists Discover the Real Reason Behind Them – SciTechDaily

By Adult Stem Cells

Harvard scientists find that the same cell types that cause goosebumps are responsible for controlling hair growth.

If youve ever wondered why we get goosebumps, youre in good company so did Charles Darwin, who mused about them in his writings on evolution. Goosebumps might protect animals with thick fur from the cold, but we humans dont seem to benefit from the reaction much so why has it been preserved during evolution all this time?

In a new study, Harvard University scientists have discovered the reason: the cell types that cause goosebumps are also important for regulating the stem cells that regenerate the hair follicle and hair. Underneath the skin, the muscle that contracts to create goosebumps is necessary to bridge the sympathetic nerves connection to hair follicle stem cells. The sympathetic nerve reacts to cold by contracting the muscle and causing goosebumps in the short term, and by driving hair follicle stem cell activation and new hair growth over the long term.

Published in the journal Cell, these findings in mice give researchers a better understanding of how different cell types interact to link stem cell activity with changes in the outside environment.

We have always been interested in understanding how stem cell behaviors are regulated by external stimuli. The skin is a fascinating system: it has multiple stem cells surrounded by diverse cell types, and is located at the interface between our body and the outside world. Therefore, its stem cells could potentially respond to a diverse array of stimuli from the niche, the whole body, or even the outside environment, said Ya-Chieh Hsu, the Alvin and Esta Star Associate Professor of Stem Cell and Regenerative Biology, who led the study in collaboration with Professor Sung-Jan Lin of National Taiwan University. In this study, we identify an interesting dual-component niche that not only regulates the stem cells under steady state, but also modulates stem cell behaviors according to temperature changes outside.

Many organs are made of three types of tissue: epithelium, mesenchyme, and nerve. In the skin, these three lineages are organized in a special arrangement. The sympathetic nerve, part of our nervous system that controls body homeostasis and our responses to external stimuli, connects with a tiny smooth muscle in the mesenchyme. This smooth muscle in turn connects to hair follicle stem cells, a type of epithelial stem cell critical for regenerating the hair follicle as well as repairing wounds.

The connection between the sympathetic nerve and the muscle has been well known, since they are the cellular basis behind goosebumps: the cold triggers sympathetic neurons to send a nerve signal, and the muscle reacts by contracting and causing the hair to stand on end. However, when examining the skin under extremely high resolution using electron microscopy, the researchers found that the sympathetic nerve not only associated with the muscle, but also formed a direct connection to the hair follicle stem cells. In fact, the nerve fibers wrapped around the hair follicle stem cells like a ribbon.

We could really see at an ultrastructure level how the nerve and the stem cell interact. Neurons tend to regulate excitable cells, like other neurons or muscle with synapses. But we were surprised to find that they form similar synapse-like structures with an epithelial stem cell, which is not a very typical target for neurons, Hsu said.

Next, the researchers confirmed that the nerve indeed targeted the stem cells. The sympathetic nervous system is normally activated at a constant low level to maintain body homeostasis, and the researchers found that this low level of nerve activity maintained the stem cells in a poised state ready for regeneration. Under prolonged cold, the nerve was activated at a much higher level and more neurotransmitters were released, causing the stem cells to activate quickly, regenerate the hair follicle, and grow new hair.

The researchers also investigated what maintained the nerve connections to the hair follicle stem cells. When they removed the muscle connected to the hair follicle, the sympathetic nerve retracted and the nerve connection to the hair follicle stem cells was lost, showing that the muscle was a necessary structural support to bridge the sympathetic nerve to the hair follicle.

In addition to studying the hair follicle in its fully formed state, the researchers investigated how the system initially develops how the muscle and nerve reach the hair follicle in the first place.

We discovered that the signal comes from the developing hair follicle itself. It secretes a protein that regulates the formation of the smooth muscle, which then attracts the sympathetic nerve. Then in the adult, the interaction turns around, with the nerve and muscle together regulating the hair follicle stem cells to regenerate the new hair follicle. Its closing the whole circle the developing hair follicle is establishing its own niche, said Yulia Shwartz, a postdoctoral fellow in the Hsu lab. She was a co-first author of the study, along with Meryem Gonzalez-Celeiro, a graduate student in the Hsu Lab, and Chih-Lung Chen, a postdoctoral fellow in the Lin lab.

With these experiments, the researchers identified a two-component system that regulates hair follicle stem cells. The nerve is the signaling component that activates the stem cells through neurotransmitters, while the muscle is the structural component that allows the nerve fibers to directly connect with hair follicle stem cells.

You can regulate hair follicle stem cells in so many different ways, and they are wonderful models to study tissue regeneration, Shwartz said. This particular reaction is helpful for coupling tissue regeneration with changes in the outside world, such as temperature. Its a two-layer response: goosebumps are a quick way to provide some sort of relief in the short term. But when the cold lasts, this becomes a nice mechanism for the stem cells to know its maybe time to regenerate new hair coat.

In the future, the researchers will further explore how the external environment might influence the stem cells in the skin, both under homeostasis and in repair situations such as wound healing.

We live in a constantly changing environment. Since the skin is always in contact with the outside world, it gives us a chance to study what mechanisms stem cells in our body use to integrate tissue production with changing demands, which is essential for organisms to thrive in this dynamic world, Hsu said.

Reference: Cell Types Promoting Goosebumps Form a Niche to Regulate Hair Follicle Stem Cells by Yulia Shwartz, Meryem Gonzalez-Celeiro, Chih-Lung Chen, H. Amalia Pasolli, Shu-Hsien Sheu, Sabrina Mai-Yi Fan, Farnaz Shamsi, Steven Assaad, Edrick Tai-Yu Lin, Bing Zhang, Pai-Chi Tsai, Megan He, Yu-Hua Tseng, Sung-Jan Lin and Ya-Chieh Hsu, 16 July 2020, Cell. DOI: 10.1016/j.cell.2020.06.031

View original post here:
Charles Darwin Investigated Goosebumps Now Harvard Scientists Discover the Real Reason Behind Them - SciTechDaily

Gear up for the change! AgeX Therapeutics Inc. (AGE) has hit the volume of 2356457 – The InvestChronicle

By Embryonic Stem Cells

Lets start up with the current stock price of AgeX Therapeutics Inc. (AGE), which is $1.26 to be very precise. The Stock rose vividly during the last session to $1.40 after opening rate of $0.99 while the lowest price it went was recorded $0.94 before closing at $0.96.

Recently in News on June 16, 2020, AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications. AgeX Therapeutics, Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Pluristyx, Inc. (Seattle, WA), an advanced therapy tools and services company serving customers in the rapidly growing fields of regenerative medicine and cellular and gene therapies, today announced they have entered into a Manufacturing, Marketing, and Distribution Agreement through which Pluristyx will undertake these activities on behalf of AgeX with respect to AgeXs research- and clinical-grade ESI brand human embryonic stem cells, sometimes referred to as hESCs. You can read further details here

AgeX Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $2.2400 on 01/02/20, with the lowest value was $0.6660 for the same time period, recorded on 04/21/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, AgeX Therapeutics Inc. shares are logging -59.87% during the 52-week period from high price, and 89.19% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $0.67 and $3.14.

The companys shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2356457 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the AgeX Therapeutics Inc. (AGE) recorded performance in the market was -30.77%, having the revenues showcasing 59.01% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 50.56M, as it employees total of 17 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.8843, with a change in the price was noted +0.1000. In a similar fashion, AgeX Therapeutics Inc. posted a movement of +8.62% for the period of last 100 days, recording 309,646 in trading volumes.

Raw Stochastic average of AgeX Therapeutics Inc. in the period of last 50 days is set at 45.74%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 77.27%. In the last 20 days, the companys Stochastic %K was 68.95% and its Stochastic %D was recorded 58.59%.

Considering, the past performance of AgeX Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -30.77%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -31.89%, alongside a downfall of -55.16% for the period of the last 12 months. The shares increased approximately by 37.45% in the 7-day charts and went down by 55.12% in the period of the last 30 days. Common stock shares were driven by 59.01% during last recorded quarter.

The rest is here:
Gear up for the change! AgeX Therapeutics Inc. (AGE) has hit the volume of 2356457 - The InvestChronicle

Why are scientists trying to manufacture organs in space? – Stuff Magazines

By Embryonic Stem Cells

Gravity can be a real downer when you are trying to grow organs.

Thats why experiments in space are so valuable. They have revealed a new perspective into biological sciences, including insights into making human tissues.

Gravity influences cellular behavior by impacting how protein and genes interact inside the cells, creating tissue that ispolarized, a fundamental step for natural organ development. Unfortunately, gravity is against us when we try to reproduce complex three dimensional tissues in the lab for medical transplantation. This is difficult because of the intrinsic limitations of bio-reactors used on Earth.

I am a stem cell biologist and interested on brain health and evolution. My lab studies how the human brain is formed inside the womb and how alterations in this process might have lifelong consequences to human behavior, such as in autism or schizophrenia. Part of that work includes growing brain cells in space.

To build organized tissues in the lab, scientists use scaffolds to provide a surface for cells to attach based on a predetermined rigid shape. For example, an artificial kidney needs a structure, or scaffold, of a certain shape for kidney cells to grow on. Indeed, this strategy helps the tissue to organize in the early stages but creates problems in the long run, such as eventual immune reactions to these synthetic scaffolds or inaccurate structures.

By contrast, in weightless conditions, cells can freely self-organize into their correct three-dimensional structure without the need for a scaffold substrate. By removing gravity from the equation, we researchers might learn new ways of building human tissues, such as cartilage and blood vessels that are scaffold-free, mimicking their natural cellular arrangement in an artificial setting. While this is not exactly what happens in the womb (after all the womb is also subject to gravity), weightless conditions does give us an advantage.

And this is precisely what is happening at the International Space Station.

These experiments help researchers optimize tissue growth for use in basic science, personalized medicine and organ transplantation.

But there are other reasons why we should manufacture organs in space. Long-term space missions create a series of physiological alterations in the body of astronauts. While some of these alterations are reversible with time, others are not, compromising future human spaceflights.

Studying astronauts bodies before and after their mission can reveal what goes wrong on their organs, but provides little insights on the mechanisms responsible for the observed alterations. Thus, growing human tissues in space can complement this type of investigation and reveal ways to counteract it.

Finally, all forms of life that we know about have evolved in the presence of microgravity. Without gravity, our brains might have evolved in a different trajectory, or our livers might not filter liquids as it does on Earth.

By recreating embryonic organ formation in space, we can anticipate how the human body in the womb would develop. There are several research initiatives going on in my lab with human brain organoids at ISS, designed to learn the impact of zero gravity on the developing human brain. These projects will have profound implications for future human colonization (can humans successfully reproduce in space?). These studies will also improve the generation of artificial organs that are used for testing drugs and treatments on Earth. Will better treatments for neurodevelopmental and neurodegenerative conditions that affects millions of people come from research in space?

Read this article:
Why are scientists trying to manufacture organs in space? - Stuff Magazines

What is Trending in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market? What are the Strategies to Boost Business in Near Years? -…

By Platelet Rich Plasma Injections

COVID-19 Updates We will be covering the overall impact of COVID -19 on the market value, market share & growth of the market and how the major players in the particular market are adapting these changes.

MarketResearchBazaar has added latest research report on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market, this report helps to analyze top manufacturers, regions, revenue, price, and also covers Industry sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

The global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026.

Download Premium Sample of the Report: http://marketresearchbazaar.com/requestSample/24200

In this report, the study analysis was given on a worldwide scale, for instance, present and traditional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesgrowth analysis, competitive analysis, and also the growth prospects of the central regions. The report gives an exhaustive investigation of this market at country &, regional levels, and provides an analysis of the industry trends in each of the sub-segments, from sales, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of sales, revenue and price.

According to Research, the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market was valued at USD xxx million in 2019, and it is expected to reach a value of USD xxx million by 2026, at a CAGR of xx% over the forecast period 2021-2026. Correspondingly, the forecast analysis of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the sales and revenue data in each of the sub-segments.

At the upcoming section, this report discusses industrial policy, economic environment, in addition to the fabrication processes and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies in these regions, from 2014 to 2026 (forecast), covering

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

South America (Brazil, Argentina, Columbia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer, the top players including

Orange County Hair Restoration Center

Colorado Surgical Center&, Hair Institute

Evolution Hair Loss Institute

Hair Sciences Center of Colorado

Hair Transplant Institute of Miami

Anderson Center for Hair

Virginia Surgical Center

Savola Aesthetic Dermatology Center

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Platelet Rich Plasma Injections

Stem Cell Therapy

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies for each application, including

Dermatology Clinics

Hospitals

If you have any special requirements, please let us know and we will offer you the report as you want.

Enquiry Before Buying: http://marketresearchbazaar.com/enquiry/24200

Major Point of TOC:

Chapter One: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Overview

Chapter Two: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Player

Chapter Three: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Type

Chapter Four: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Application

Chapter Five: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Sales Channel

Chapter Six: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Region

Chapter Seven: Profile of Leading Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players

Chapter Eight: Upstream and Downstream Analysis of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Chapter Nine: Development Trend of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies (2020-2029)

Chapter Ten: Appendix

Read Full Report: http://marketresearchbazaar.com/requestSample/24200

If you have any special requirements, please let us know and we will offer you the report as you want.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

Follows to Twitter : https://twitter.com/BazaarMrb

Follows to Linkdin : https://www.linkedin.com/company/market-research-bazaar-vrrb/

See the article here:
What is Trending in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market? What are the Strategies to Boost Business in Near Years? -...

COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model – Tyler Morning Telegraph

By Stem Cell Medicine

HOUSTON, July 21, 2020 /PRNewswire/ --FibroGenesis announced today new data supporting use of its PneumoBlast product in the battle against COVID-19.Using the widely accepted bleomycin model of lung scarring (fibrosis), Company scientists have demonstrated the administration and use of PneumoBlast induced a 51% reduction of lung fibrosis,which was statistically significant (p < .005). Importantly, when PneumoBlast was compared head to head with bone marrow derived mesenchymal stem cells (BMSCs) for COVID-19, PneumoBlast was 221% more effective. In producing the potent anti-inflammatory protein interleukin 1 receptor antagonist, which is believed to be the mechanism of scar tissue prevention by BMSC therapies currently in development, PneumoBlast was 192% more effective than BMSCs which was again, statistically significant(p < .005).

During an interview with Healthline.com, Dr. Lori Shah, transplant pulmonologist at New York-Presbyterian/Columbia University Irving Medical Center, stated "Holes in the lungs likely refers to an entity that has been dubbed 'post-COVID fibrosis,' otherwise known as post-ARDS [acute respiratory distress syndrome] fibrosis, which is irreversible and can result in severe functional limitations from patients, such as cough, shortness of breath, and need for oxygen." It has been reported that pulmonary fibrosis due to COVID-19 is occurring in increasing numbers of patients in their 20s and 30s.

"COVID-19 represents a new clinical entity which not only causes death through lung inflammation, but in some patients causes permanent lung injury through stimulation of scarring," said Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis. "The prospects that our cell therapy approach not only possesses therapeutic effects on animal models of the acute stage of COVID-19, but also benefits the long-term pathology, has our research team extremely excited."

"As the scientific and medical community is discovering more about the biological and medical consequences of the COVID-19 infection, FibroGenesis is eager to contribute to the therapeutic cure options currently being created to fight this global war against an invisible enemy," commented Pete O'Heeron, President/CEO of FibroGenesis. "While we are excited about potential vaccines in the pipeline, the fact remains that there are 3.8 million confirmed cases of COVID-19 in the U.S. and we do not know what the long-term outcomes for these patients will be. To our knowledge, we are the only cell therapy company which is creating a therapy to resolve the initial pathology of infection and also proactively tackling its long-term consequences."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 235+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit http://www.Fibro-Genesis.com.

Here is the original post:
COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model - Tyler Morning Telegraph

Growing Demand for Anti Aging Medicine Market to Significantly Increase Revenues Through 2026 – 3rd Watch News

By Stem Cell Medicine

Longer life-expectancy is a cumulative effect of a healthy lifestyle and favorable environmental conditions. A trend of continuously increasing life expectancy has been a witness since a decade, primarily because of advances in medical sciences and treatment of chronic life-threatening diseases, availability of clean water and environment and other factors. This trend is projected to further show even more exponential growth graph owing to the anti-aging medicines, stem cell therapeutics, genetic screening and interventions, and high-tech biomedicines.

American Academy of Anti-Aging Medicine claimed that anti-aging medicines can add up to 10-20 years to the life expectancy of a human. Today, a combination of calorie-restricted diet, regular exercise, and anti-aging medicines are claimed to slow the process of senescence and aging. Various medicines used against the treatment of acute or chronic diseases can be considered as anti-aging medicines, however, to define anti-aging medicine market we have considered only the drugs that are directly prescribed and used for delaying the effects of aging.

To remain ahead of your competitors, request for a sample [emailprotected]https://www.persistencemarketresearch.com/samples/26233

The constantly growing demand to look young in old individuals and to remain young and youthful in young people drive the anti-aging market. The influence of aesthetics from the fashion and television industry propel the demand to retain the features and energy of younger age in old people. Additionally, the increasing number of anti-aging medicine manufacturers in the decade contribute to higher availability of the anti-aging medicine resulting in expansion of the global anti-aging medicine market. However, skeptical approach to anti-aging medicine as being an external stimulator of cell-cycles is a restraint to the expansion of anti-aging medicine market.

The global Anti-aging medicine market is segmented on basis of product type, age group, distribution channel, and region:

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/26233

The rising demand for beauty consciousness amongst people and the desire to stay young is the primary factor fueling the growth of anti-aging medicines in the market. The acclaimed benefits of the products and affordability along with regional presence compel the demand for anti-aging medicine in the global market. Hormonal replacement therapy segment in product type is expected to account maximum market share in the terms of revenue in the global anti-aging medicine market. However, antioxidant therapy segment in product type is expected to grow with the highest CAGR over the forecast years owing to the rising awareness about the plethora of benefits of antioxidants in anti-aging among the public. On the basis of the route of administration, the global anti-aging medicine market is segmented as oral, injectable and topical, out of which oral segment is expected to generate maximum revenue share over the forecast period. As per the distribution channel, the global anti-aging medicine market is segmented as hospital pharmacies, retail pharmacies, e-commerce, and drug stores. The e-commerce segment in the distribution channel is estimated to grow with the highest CAGR over the forecast time.

Regionally, the global anti-aging medicine market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America anti-aging medicine market is projected to account for the largest market share in the terms of revenue in the global anti-aging medicine market owing to the higher healthcare expenditure and presence of numerous manufacturers. Europe is expected to hold the second largest share in the global anti-aging medicine market during the forecast period because of the growing geriatric population and higher spending on healthcare products and supplements. MEA anti-aging medicine market is expected to witness sluggish growth over the forecast time owing to the limited presence of manufacturers and lower healthcare expenditure. Asia Pacific is projected to grow with the highest CAGR over the forecast years in the global anti-aging medicine market due to higher demand from end users and regional penetration of the key players in the region.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/26233

Some of the players operating in the global anti-aging medicine market are

Originally posted here:
Growing Demand for Anti Aging Medicine Market to Significantly Increase Revenues Through 2026 - 3rd Watch News

COVID-19 Impact on Regenerative Medicine Market 2020: Global Industry Size, Growth, Emerging Trends, Business Opportunities, SWOT Analysis by Top Key…

By Stem Cell Medicine

The report provides 360 analysis ofRegenerative Medicine Marketfrom view of manufacturers, regions, product types and end industries.

The research report analyses and provides the historical data along with current performance of the global Regenerative Medicine industry, and estimates the future trend of Regenerative Medicine market on the basis of this detailed study.

Get Sample Copy @https://www.orianresearch.com/request-sample/574056

Reasons for Buying this Report: This report provides pin-point analysis for changing competitive dynamics It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow It helps in understanding the key product segments and their future It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

The report covers projection as well as evaluation for the Regenerative Medicine market on a global as well as regional level. The study offers Regenerative Medicine historic information of 2017 in addition to a forecast from 2018 to 2025 based upon both quantity (Million Units) as well as revenue (USD Million).

The research study includes chauffeurs and restraints for the Regenerative Medicine market along with the influence they carry the demand over the projection period. Additionally, the record includes the research of opportunities offered in the Regenerative Medicine market on a global level.

Complete report on Regenerative Medicine Market report spread across 152 pages, profiling 20 companies and supported with tables and figures available, Do Inquire more if any on this report @https://www.orianresearch.com/enquiry-before-buying/574056

Moreover, the report also offers key insights on the latest developments in the Regenerative Medicine Market that are transforming global industry. The report on the global Regenerative Medicine Market shows how the market performed in past and how it is expected to perform in the next few years.

The global Regenerative Medicine market is valued at 5350 million USD in 2017 and is expected to reach 19000 million USD by the end of 2025, growing at a CAGR of 23.5% between 2017 and 2025.

USA is the largest market of regenerative medicine, which occupies 51.09 percent of global regenerative medicine market share in 2015. It is followed by EU, which has around 16.66 percent of the global total industry. Other main regions which take important part in this industry include Japan and China.

Dominant Regenerative Medicine Market TOP Players: Competitive Insights

DePuy Synthes Medtronic ZimmerBiomet Stryker Acelity MiMedx Group Organogenesis UniQure Cellular Dynamics International Osiris Therapeutics Vcanbio Gamida Cell Golden Meditech Cytori Celgene Vericel Corporation Guanhao Biotech Mesoblast Stemcell Technologies Bellicum Pharmaceuticals

Global Regenerative Medicine Market report also includes Regenerative Medicine Market Business Overview. It also includes Regenerative Medicine Market by Applications and Type, Regenerative Medicine Revenue, Sales and Price and Regenerative Medicine Business Share. This report of Regenerative Medicine Market research also consists Global Regenerative Medicine Market Competition, by Regenerative Medicine market revenue of regions, sales and by Regenerative Medicine industry Competitive Players like.(2013-2018)

Get Direct Copy of this Report @https://www.orianresearch.com/checkout/574056

Global Regenerative Medicine Market: Type Outlook:

Cell Therapy Tissue Engineering Biomaterial Other

Global Regenerative Medicine Market: Application Outlook:

Dermatology Cardiovascular CNS Orthopedic Others

Global Regenerative Medicine Market: Regional Outlook:

Europe Regenerative Medicine Market(Germany, France, Italy, Russia and UK)

North America Regenerative Medicine Market (Canada, USA and Mexico) Latin America Regenerative Medicine Market (Middle and Africa). Regenerative Medicine Market in Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Asia-Pacific Regenerative Medicine Market (South-east Asia, China, India, Korea and Japan).

Report on (2018-2025 Regenerative Medicine Market Report) mainly covers 15 sections acutely display the global Regenerative Medicine market:

Chapter 1: Describe Regenerative Medicine Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Chapter 2: Analyze the top manufacturers of Regenerative Medicine, with sales, revenue, and price of Regenerative Medicine, in 2016 and 2017; Chapter 3: Display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017; Chapter 4: Show the global market by regions, with sales, revenue and market share of Regenerative Medicine, for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9: Analyze and talked about the key regions, with sales, revenue and market share by key countries in these regions. Chapter 10 and 11: Show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018; Chapter 12: In Chapter Eleven Regenerative Medicine market forecast, by regions, type and application, with sales and revenue, from 2018 to 2025; Chapter 13, 14 and 15: Describe Regenerative Medicine sales channel, distributors, traders, dealers, appendix and data source.

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez Vice President Global Sales & Partner Relations Orian Research Consultants US: +1 (832) 380-8827 | UK: +44 0161-818-8027 Email:[emailprotected] Website: http://www.orianresearch.com/

See the rest here:
COVID-19 Impact on Regenerative Medicine Market 2020: Global Industry Size, Growth, Emerging Trends, Business Opportunities, SWOT Analysis by Top Key...

→←